Cohance Lifesciences reports 13% revenue growth in Q1

Cohance Lifesciences Limited reported 13% year-on-year revenue growth in Q1 FY26. Excluding inventory de-stocking in Pharma CDMO, revenue growth exceeded 25%.

The Pharma CDMO segment saw 1% revenue growth, but adjusting for inventory de-stocking, it delivered over 30% growth.

Niche technology revenue share increased from mid-teens in FY25 to over 20% in Q1 FY26, projected to approach mid-20s by FY26.

The company invested INR559 million in capex and generated INR2.3 billion in free cash flow, ending with INR4.4 billion cash.